Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia

European Urology
L M Eri, P Urdal

Abstract

The effect of the nonsteroidal antiandrogen Casodex (176334) on a number of risk factors for cardiovascular diseases was investigated in a double-blind, randomized, placebo-controlled study comprising 27 evaluable patients with benign prostatic hyperplasia who received either placebo or Casodex at a dosage of 50 mg daily for 24 weeks. We hypothesized that the 30-35% increase in serum levels of testosterone and estradiol seen during treatment with Casodex might induce changes in various risk factors. We found no statistically significant change in total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglycerides. Apolipoproteins A1 and B also remained unchanged, along with plasma concentrations of fibrinogen and plasminogen activator inhibitor 1. Casodex has the potential to become an important drug for treatment of prostatic diseases. Our study does not suggest that the drug is associated with an increased cardiovascular risk.

Citations

Mar 29, 2011·BJU International·Edward R JefferiesAmit Bahl
Aug 26, 1998·The Journal of Clinical Endocrinology and Metabolism·E Diamanti-KandarakisA J Duleba
Apr 21, 2010·Current Opinion in Endocrinology, Diabetes, and Obesity·Jason E Faris, Matthew R Smith
Apr 18, 2003·Endocrine Reviews·Fredrick C W Wu, Arnold von Eckardstein
Oct 25, 2002·Cardiovascular Drug Reviews·Wolfgang Weidemann, Hartmut Hanke

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.